Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8 Head & Neck 6 Sarcoma 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1

Conditions

Prostatic Neoplasms 292 Urinary Bladder Neoplasms 39 Neoplasm Metastasis 35 Carcinoma, Non-Small-Cell Lung 24 Carcinoma, Transitional Cell 23 Neoplasms 21 Breast Neoplasms 20 Lung Neoplasms 13 Carcinoma, Renal Cell 13 Ovarian Neoplasms 12 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Non-Muscle Invasive Bladder Neoplasms 10 Melanoma 9 Small Cell Lung Carcinoma 7 Salivary Gland Neoplasms 7 Prostatic Neoplasms, Castration-Resistant 7 Head and Neck Neoplasms 7 Esthesioneuroblastoma, Olfactory 7 Esophageal Neoplasms 7 Colorectal Neoplasms 7 Urethral Neoplasms 6 Uterine Cervical Neoplasms 5 Triple Negative Breast Neoplasms 5 Prostate Cancer Metastatic 5 Pancreatic Neoplasms 5 Metastatic Castration-resistant Prostate Cancer 5 Kidney Neoplasms 5 Adenocarcinoma 5 Sarcoma 4

Interventions

Peripheral Blood Stem Cell Transplantation 6 Cyclophosphamide 6 fludarabine phosphate 5 Nivolumab 5 Mycophenolic Acid 5 Carboplatin 5 Whole-Body Irradiation 4 Radiotherapy 4 Filgrastim 4 Cyclosporine 4 Gemcitabine 3 Cisplatin 3 Busulfan 3 Antilymphocyte Serum 3 cabozantinib 2 cabazitaxel 2 Voriconazole 2 Thiotepa 2 Therapeutics 2 Standard of Care 2 Sirolimus 2 Polymerase Chain Reaction 2 Mitomycin 2 Methylprednisolone 2 Methotrexate 2 Melphalan 2 Itraconazole 2 Immunoglobulin G 2 Goserelin 2 Flow Cytometry 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Docetaxel × Genitourinary × Clear all

NCT06551324 2026-05-05

MEVPRO-1

Pfizer

Phase 3 Active not recruiting

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡